CIK 0001635088
- Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- Operating
- EIN
- 981173944
- Phone
- +44 12955950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $70,369,463
- in 12 filings, $45.5M under 10b5-1 plans
Net −$70,369,463. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-28 | QVT Financial LP 10% owner | Sale | −446,394 | $11.55 | $5.2M | 5,023,787 |
| 2023-09-28 | Gold Daniel Allen Director | Sale | −8,957 | $11.55 | $103K | 100,804 |
| 2023-09-28 | Gold Daniel Allen Director | Sale | −2,285,783 | $11.55 | $26.4M | 25,724,561 |
| 2023-09-28 | Gold Daniel Allen Director | Sale | −3,059,368 | $11.55 | $35.3M | 34,430,591 |
| 2023-09-28 | Gold Daniel Allen Director | Sale | −3,094,899 | $11.55 | $35.7M | 34,830,463 |
| 2023-09-28 | Gold Daniel Allen Director | Sale | −1,104,599 | $11.55 | $12.8M | 12,431,330 |
| 2023-09-28 | Gold Daniel Allen Director | Sale | −446,394 | $11.55 | $5.2M | 5,023,787 |
| 2023-09-28 | Gline Matthew CEO | Other disposition | −10,243 | $12.67 | $130K | 1,041,240 |
| 2023-09-28 | Ramaswamy Vivek 10% owner | Other disposition | −61,947 | $12.67 | $785K | 54,788,110 |
| 2023-09-28 | Kumar Rakhi Chief Accounting Officer | Other disposition | −92 | $12.67 | $1K | 196,624 |
| 2023-09-27 | Venker Eric President & COO | Option exercise | +500,000 | $3.85 | $1.9M | 1,095,397 |
| 2023-09-27 | Venker Eric President & COO | Sale | −500,000 | $13.02 | $6.5M | 595,397 |
| 2023-09-27 | Venker Eric President & COO | Option exercise · Stock Option (Right to Buy) | −500,000 | 13,823,184 | ||
| 2023-09-27 | Sukhatme Mayukh Pres&Chief Investment Officer | Option exercise | +27,790 | 3,217,750 | ||
| 2023-09-27 | Sukhatme Mayukh Pres&Chief Investment Officer | Option exercise · Capped Value Appreciation Rights | −53,033 | $6.40 | $339K | 2,015,263 |
| 2023-09-27 | Sukhatme Mayukh Pres&Chief Investment Officer | Option exercise · Capped Value Appreciation Rights | −28,411 | $11.50 | $327K | 1,335,300 |
| 2023-09-27 | Gline Matthew CEO | Option exercise | +17,762 | 1,051,483 | ||
| 2023-09-27 | Gline Matthew CEO | Option exercise · Capped Value Appreciation Rights | −28,411 | $6.40 | $182K | 1,164,836 |
| 2023-09-27 | Gline Matthew CEO | Option exercise · Capped Value Appreciation Rights | −47,351 | $11.50 | $545K | 2,225,501 |
| 2023-09-27 | Ramaswamy Vivek 10% owner | Option exercise | +119,534 | 54,850,057 |
Page 37 of 38 · 748 trades